Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.46 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 4/20 | 0.40 |
| ▸ | JAK1 | P23458 | 4/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6155283 | 1.00 | KDM4D (0.49) | KDM4DTRPA1DRD2AAK1EGLN2 | |
| SCHEMBL6153457 | 1.00 | KDM4D (0.49) | KDM4DTRPA1DRD2AAK1EGLN2 | |
| SCHEMBL31206154 | 0.87 | NPC1 (0.48) | DRD2KDM1AMAOBJAK2JAK1 | |
| SCHEMBL29665918 | 0.87 | AR (0.48) | TRPA1DRD2 | |
| SCHEMBL24193168 | 0.87 | HDAC8 (0.49) | DRD2AAK1KDM1AMAOBKCNA3 | |
| SCHEMBL30054519 | 0.87 | HDAC8 (0.49) | DRD2AAK1KDM1AMAOBKCNA3 | |
| SCHEMBL6154416 | 0.86 | SUV39H2 (0.47) | KDM4DDRD2AAK1KDM1AMAOB | |
| SCHEMBL6154460 | 0.86 | SUV39H2 (0.47) | KDM4DDRD2AAK1KDM1AMAOB | |
| SCHEMBL6154412 | 0.86 | SUV39H2 (0.47) | KDM4DDRD2AAK1KDM1AMAOB | |
| SCHEMBL6154752 | 0.84 | GPR119 (0.44) | KDM4DTRPA1DRD2AAK1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | KDM4D 2098/4885TRPA1 691/4885DRD2 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.